Certara's scientific consultants support strategic drug development decisions and submission-ready analyses.
From Discovery through Development
Supporting Over Seventeen Recent Drug Approvals with Model Based Drug Development
Certara’s Pharsight Consulting Services is applying quantative models to decision making, helping accelerate FDA approvals.
Using an Exposure-Response driven Tumor Growth Inhibition model based on Phase II data to demonstrate non-inferiority of an unobserved dose in Phase III.
Our global Consulting Services team has unparalleled experience across all development phases and in all major therapeutic areas, spanning 80+ disease indications and 130 drug classes. We have collaborated with clients to support key trial design and program-level development decisions at every point along the regulatory timeline.
We've highlighted a few key case studies here - just click the title to get the PDF. To find more case studies and other publications, explore our Resource Library at the bottom of the page, or contact us today to discuss your interests with one of our experts.